Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 12 (4) |
| Completed vs Stopped Early | 3 / 3 (14.3%) |
| Median Closed Actual Enrollment | 89 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Explore interactive annual charts and M&A subsidiary rollups in the Gruppo Italiano Malattie EMatologiche dell'Adulto Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.